Antonietta Salerno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antonietta Salerno has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Arutha Kulasinghe
The University of Queensland
1 shared publication - Aysen Yuksel
Tumour Bank, Children’s Hospital at Westmead, Westmead, Australia
1 shared publication Blake J. Cochran
School of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, Australia
1 shared publicationCharlotte McHenry
School of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, Australia
1 shared publication- Chelsea Mayoh
Children’s Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Kensington, Australia
1 shared publication Daniel Catchpoole
Tumour Bank, Children’s Hospital at Westmead, Westmead, Australia
1 shared publication
Latest Publications
- Open Access
- 12 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma
Anti-disialoganglioside (GD2) antibody therapy has provided clinical benefit to patients with neuroblastoma however efficacy is likely impaired by the immunosuppressive tumor microenvironment. We have previously defined a link between intratumoral copper levels and immune evasion. Here, we report that adjuvant copper chelation potentiates anti-GD2 antibody therapy to confer durable tumor control in immunocompetent models of neuroblastoma. Mechanistic studies reveal copper chelation creates an immune-primed tumor microenvironment through enhanced infiltration and activity of Fc-receptor-bearing cells, specifically neutrophils which are emerging as key effectors of antibody therapy. Moreover, we report copper sequestration by neuroblastoma attenuates neutrophil function which can be successfully reversed using copper chelation to increase pro-inflammatory effector functions. Importantly, we repurpose the clinically approved copper chelating agent Cuprior as a non-toxic, efficacious immunomodulatory strategy. Collectively, our findings provide evidence for the clinical testing of Cuprior as an adjuvant to enhance the activity of anti-GD2 antibody therapy and improve outcomes for patients with neuroblastoma.
- 12 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-20
Open AccessCopper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma
Anti-disialoganglioside (GD2) antibody therapy has provided clinical benefit to patients with neuroblastoma however efficacy is likely impaired by the immunosuppressive tumor microenvironment. We have previously defined a link between intratumoral copper levels and immune evasion. Here, we report that adjuvant copper chelation potentiates anti-GD2 antibody therapy to confer durable tumor control in immunocompetent models of neuroblastoma. Mechanistic studies reveal copper chelation creates an immune-primed tumor microenvironment through enhanced infiltration and activity of Fc-receptor-bearing cells, specifically neutrophils which are emerging as key effectors of antibody therapy. Moreover, we report copper sequestration by neuroblastoma attenuates neutrophil function which can be successfully reversed using copper chelation to increase pro-inflammatory effector functions. Importantly, we repurpose the clinically approved copper chelating agent Cuprior as a non-toxic, efficacious immunomodulatory strategy. Collectively, our findings provide evidence for the clinical testing of Cuprior as an adjuvant to enhance the activity of anti-GD2 antibody therapy and improve outcomes for patients with neuroblastoma.